{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antihyperglycemic+medication&page=2",
    "query": {
      "intervention": "Antihyperglycemic medication",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 151,
    "total_pages": 16,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antihyperglycemic+medication&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antihyperglycemic+medication&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T10:13:04.470Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00994682",
      "title": "University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis",
        "Nonalcoholic Fatty Liver Disease",
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Pioglitazone study drug",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone Open Label",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 176,
      "start_date": "2008-12",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-04-05",
      "last_synced_at": "2026-10-06T10:13:04.470Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00994682"
    },
    {
      "nct_id": "NCT05220917",
      "title": "Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiovascular Events",
        "Type2 Diabetes",
        "Renal Disease"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "DPP-4 inhibitor",
          "type": "DRUG"
        },
        {
          "name": "GLP-1RA",
          "type": "DRUG"
        },
        {
          "name": "2nd generation SU",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 781430,
      "start_date": "2021-08-01",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-06T10:13:04.470Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05220917"
    },
    {
      "nct_id": "NCT00351234",
      "title": "Carnitine Levels and Carnitine Supplementation in Type I Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Diabetes Mellitus, Type I",
        "Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Carnitine (drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Mercy Hospital Kansas City",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "7 Years to 21 Years"
      },
      "enrollment_count": 200,
      "start_date": "2004-10",
      "completion_date": "2007-04",
      "has_results": false,
      "last_update_posted_date": "2012-02-28",
      "last_synced_at": "2026-10-06T10:13:04.470Z",
      "location_count": 1,
      "location_summary": "Kansas City, Missouri",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00351234"
    },
    {
      "nct_id": "NCT06132477",
      "title": "Impact GLP-1 Agonists Following Bariatric",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Morbid Obesity",
        "Metabolic Syndrome",
        "Diabetes Mellitus",
        "Hypertension",
        "Obstructive Sleep Apnea of Adult"
      ],
      "interventions": [
        {
          "name": "GLP-1 receptor agonist",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Missouri-Columbia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2024-02-01",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-10-06T10:13:04.470Z",
      "location_count": 1,
      "location_summary": "Columbia, Missouri",
      "locations": [
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06132477"
    },
    {
      "nct_id": "NCT00859898",
      "title": "Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin XR",
          "type": "DRUG"
        },
        {
          "name": "dapagliflozin matching Placebo",
          "type": "DRUG"
        },
        {
          "name": "metformin HCl Modified Release matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 1093,
      "start_date": "2009-04",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2016-07-07",
      "last_synced_at": "2026-10-06T10:13:04.470Z",
      "location_count": 64,
      "location_summary": "Ozark, Alabama • Tempe, Arizona • Concord, California + 53 more",
      "locations": [
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00859898"
    },
    {
      "nct_id": "NCT00308139",
      "title": "Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "exenatide, long acting release",
          "type": "DRUG"
        },
        {
          "name": "exenatide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 303,
      "start_date": "2006-04",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2015-08-26",
      "last_synced_at": "2026-10-06T10:13:04.470Z",
      "location_count": 24,
      "location_summary": "Encino, California • La Jolla, California • San Diego, California + 21 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00308139"
    },
    {
      "nct_id": "NCT05305911",
      "title": "Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Attack",
        "Enlarged Heart"
      ],
      "interventions": [
        {
          "name": "SGLT-2 inhibitors",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Minneapolis Heart Institute Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 81,
      "start_date": "2022-08-03",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-10-06T10:13:04.470Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05305911"
    },
    {
      "nct_id": "NCT01790438",
      "title": "A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "LY2605541",
          "type": "DRUG"
        },
        {
          "name": "Human Insulin NPH",
          "type": "DRUG"
        },
        {
          "name": "Oral Antihyperglycemic Medications (OAM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 641,
      "start_date": "2013-03",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2018-05-03",
      "last_synced_at": "2026-10-06T10:13:04.470Z",
      "location_count": 20,
      "location_summary": "Tempe, Arizona • Concord, California • Fresno, California + 17 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Lancaster",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01790438"
    },
    {
      "nct_id": "NCT05033054",
      "title": "Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Kidney Disease, Chronic",
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "SGLT2 inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 33,
      "start_date": "2022-01-01",
      "completion_date": "2025-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-06T10:13:04.470Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05033054"
    },
    {
      "nct_id": "NCT03779048",
      "title": "Use of Medication to Improve Weight Loss in Suboptimal Early Responders to Behavioral Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Behavioral Treatment",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Phentermine 15 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 147,
      "start_date": "2019-07-15",
      "completion_date": "2022-05-25",
      "has_results": true,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-10-06T10:13:04.470Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03779048"
    }
  ]
}